Sangamo Therapeutics (LTS:0R1D) Total Liabilities: $78.92 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1D Sangamo Therapeutics Inc LTS:0R1D
35 GF Score
Price $0.11
GF Value $0.19
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sangamo Therapeutics Total Liabilities?

Sangamo Therapeutics LTS:0R1D +12.14% 35 Total Liabilities is $78.92 Mil as of Mar. 2026. GuruFocus rates LTS:0R1D with a GF Score™ of 35/100 and a GF Value™ of $0.19 (Possible Value Trap). The stock has 5 warning signs investors should review.

Sangamo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $78.92 Mil.

Sangamo Therapeutics's quarterly Total Liabilities declined from Sep. 2025 ($82.40 Mil) to Dec. 2025 ($74.01 Mil) but then increased from Dec. 2025 ($74.01 Mil) to Mar. 2026 ($78.92 Mil).

Sangamo Therapeutics's annual Total Liabilities declined from Dec. 2023 ($82.43 Mil) to Dec. 2024 ($78.87 Mil) and declined from Dec. 2024 ($78.87 Mil) to Dec. 2025 ($74.01 Mil).

Sangamo Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Sangamo Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics Total Liabilities Chart

Sangamo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 346.58 267.55 82.43 78.87 74.01

Sangamo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.26 77.96 82.40 74.01 78.92
LTS:0R1D
35GF Score
Sangamo Therapeutics Inc LTS:0R1D
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sangamo Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sangamo Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.466+(25.093+0.58
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+5.874+0+0)
=74.01

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=59.745--14.268
=74.01

Sangamo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=53.134+(19.332+0.58
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+5.874+0+0)
=78.92

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=59.965--18.955
=78.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $78.92 Mil mean?
Sangamo Therapeutics (LTS:0R1D) has a Total Liabilities of $78.92 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sangamo Therapeutics and its competitors.
Is Sangamo Therapeutics' Total Liabilities too high?
Sangamo Therapeutics' current Total Liabilities is $78.92 Mil. Overall, Sangamo Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sangamo Therapeutics' Total Liabilities compare to SER and ABVC?
Sangamo Therapeutics' Total Liabilities of $78.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sangamo Therapeutics and its competitors. Sangamo Therapeutics's current Total Liabilities is $78.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sangamo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sangamo Therapeutics (LTS:0R1D) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.11 — trading 42.2% below its estimated fair value. The current Total Liabilities is $78.92 Mil. Sangamo Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sangamo Therapeutics (LTS:0R1D), the current Total Liabilities is $78.92 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.11 is trading 42.2% below its estimated GF Value™ of $0.19. GuruFocus considers Sangamo Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0R1D:

  • Total Liabilities: $78.92 Mil
  • GF Value™: $0.19 vs. price of $0.11 (42.2% below fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USAGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
35GF Score

Get the complete analysis for LTS:0R1D

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.19
GF Value